The University of Chicago Medicine Comprehensive Cancer Center (UCCCC) is submitting this competitive renewal application for its Cancer Center Support Grant for Years 43-47. The mission of the UCCCC is to elucidate the determinants of cancer, to develop cures for cancer, and to prevent cancer through research, clinical care, education, and community engagement. Our cancer research programs emphasize translational and transdisciplinary research, and we pursue this goal by promoting collaboration among a diverse and dedicated team of outstanding basic, translational, clinical, and population researchers. The 166 members of the UCCCC are organized into five established programs, all with a translational focus (Molecular Mechanisms of Cancer; Immunology and Cancer; Clinical and Experimental Therapeutics; Advanced Imaging; and Cancer Prevention and Control). Clinical research is a major focus of multidisciplinary activity at the UCCCC. The UCCCC has an extensive record in conducting all phases of clinical trials, and was awarded a U10 NCTN Lead Academic Participating Site (LAPS) award from the NCI. In addition, the UCCCC is a full member of the Alliance for Clinical Trials in Oncology, and the Children's Oncology Group (COG), and participates in NRG Oncology studies as a LAPS main member. In 2016, 914 individual patients were accrued to therapeutic protocols, with 383 accrued to investigator-initiated trials. In the period since the last review (2013-2016), the UCCCC contributed 2,121 peer-reviewed publications. Members are supported by $40.5 million (DC) in peer- reviewed funding, and $23.7 million in non-peer-reviewed funding. Funds are requested in this application for Program Leaders; Leadership, Planning and Evaluation; Developmental Funds, Administration, Clinical Protocol and Data Management; the Protocol Review and Monitoring System, Community Outreach and Engagement; Cancer Research Career Enhancement and Related Activities; and 10 shared resources (Bioinformatics, Biostatistics; Cytometry and Antibody Technology; Genomics; Human Immunologic Monitoring and cGMP; Human Tissue Resource Center; Integrated Microscopy; Integrated Small Animal Imaging Research Resource; Pharmacology; and Transgenic Mouse/Embryonic Stem Cell Facilities). Through an in-depth institutional review and multi-faceted strategic planning process, the UCCCC has new and strong institutional commitments, and a stable and experienced leadership team, and has developed and implemented a comprehensive strategic plan. Future development will focus on three major initiatives, which prioritize and accelerate laboratory, clinical and translational, and community-based cancer research: 1) developing new biomarkers, novel treatments, and new interventions to prevent cancer; 2) efficiently integrating effective treatments and interventions into medical practice; and 3) assessing the impact of these new approaches on health outcomes, and addressing cancers relevant to our catchment area. Underpinning each of these initiatives is computation-based models for cancer research and care.

Public Health Relevance

The mission of the UCCCC is to elucidate the determinants of cancer, to develop cures for cancer, and to prevent cancer. In addition, we provide education and training for basic scientists, physicians, and clinical investigators, and local health professionals, as well as develop and implement community-based cancer education and outreach programs. Our mission is fulfilled in an environment that values diversity, the development of the next generation of physicians and scientists, and delivering comprehensive and compassionate patient care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014599-45S1
Application #
10063249
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-09-01
Project End
2023-03-31
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:
Wu, Chengyue; Pineda, Federico; Hormuth 2nd, David A et al. (2018) Quantitative analysis of vascular properties derived from ultrafast DCE-MRI to discriminate malignant and benign breast tumors. Magn Reson Med :
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Ni, Kaiyuan; Lan, Guangxu; Chan, Christina et al. (2018) Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun 9:2351
Meisel, Marlies; Hinterleitner, Reinhard; Pacis, Alain et al. (2018) Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557:580-584
Webber, Jemma L; Zhang, Jie; Massey, Alex et al. (2018) Collaborative repressive action of the antagonistic ETS transcription factors Pointed and Yan fine-tunes gene expression to confer robustness in Drosophila. Development 145:
Wei, Jiangbo; Liu, Fange; Lu, Zhike et al. (2018) Differential m6A, m6Am, and m1A Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm. Mol Cell 71:973-985.e5
Boisclair Lachance, Jean-François; Webber, Jemma L; Hong, Lu et al. (2018) Cooperative recruitment of Yan via a high-affinity ETS supersite organizes repression to confer specificity and robustness to cardiac cell fate specification. Genes Dev 32:389-401
Szmulewitz, Russell Z; Peer, Cody J; Ibraheem, Abiola et al. (2018) Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol 36:1389-1395
Maron, Steven B; Alpert, Lindsay; Kwak, Heewon A et al. (2018) Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. Cancer Discov 8:696-713

Showing the most recent 10 out of 668 publications